BIOHAVEN PHARMACTL HLDG CO L's ticker is BHVN and the CUSIP is G11196105. A total of 204 filers reported holding BIOHAVEN PHARMACTL HLDG CO L in Q2 2019. The put-call ratio across all filers is 0.22 and the average weighting 0.8%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2022 | $3,099,000 | +3.7% | 20,500 | 0.0% | 0.53% | +9.3% |
| Q2 2022 | $2,987,000 | +22.9% | 20,500 | 0.0% | 0.49% | +47.7% |
| Q1 2022 | $2,431,000 | -13.9% | 20,500 | 0.0% | 0.33% | -7.6% |
| Q4 2021 | $2,825,000 | -0.8% | 20,500 | 0.0% | 0.36% | -8.0% |
| Q3 2021 | $2,848,000 | +43.1% | 20,500 | 0.0% | 0.39% | +46.0% |
| Q2 2021 | $1,990,000 | +42.0% | 20,500 | 0.0% | 0.26% | +33.2% |
| Q1 2021 | $1,401,000 | +8.9% | 20,500 | +36.7% | 0.20% | +0.5% |
| Q4 2020 | $1,286,000 | +31.9% | 15,000 | 0.0% | 0.20% | +13.1% |
| Q3 2020 | $975,000 | -11.1% | 15,000 | 0.0% | 0.18% | -15.0% |
| Q2 2020 | $1,097,000 | +115.1% | 15,000 | 0.0% | 0.21% | +76.1% |
| Q1 2020 | $510,000 | -37.6% | 15,000 | 0.0% | 0.12% | -15.8% |
| Q4 2019 | $817,000 | +30.5% | 15,000 | 0.0% | 0.14% | +21.9% |
| Q3 2019 | $626,000 | +138.0% | 15,000 | +150.0% | 0.11% | +142.6% |
| Q2 2019 | $263,000 | – | 6,000 | – | 0.05% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| RP Management, LLC | 1,111,111 | $154,344,000 | 72.03% |
| Knoll Capital Management, LLC | 856,844 | $119,024,000 | 59.36% |
| ORACLE INVESTMENT MANAGEMENT INC | 2,124,055 | $295,053,000 | 36.73% |
| ARS Investment Partners, LLC | 466,668 | $64,825,000 | 6.49% |
| KINGDON CAPITAL MANAGEMENT, L.L.C. | 365,373 | $50,754,000 | 6.18% |
| INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 176,400 | $24,490,000 | 5.91% |
| SILVERARC CAPITAL MANAGEMENT, LLC | 61,897 | $8,598,000 | 4.86% |
| DAFNA Capital Management LLC | 88,100 | $12,238,000 | 3.25% |
| Avidity Partners Management LP | 934,200 | $129,770,000 | 2.88% |
| Eventide Asset Management | 1,325,000 | $184,056,000 | 2.43% |